|
|
|
Agenda
Day One - 16 October
|
08:55 |
Welcome |
|
Cancer Biomarkers
Chaired by Herbert Fritsche, MD Anderson Cancer Centre |
|
09:00 |
Assays for Circulating Tumour Cells and Clinical Utility
Herbert Fritsche, Chief of Clinical Chemistry, MD Anderson Cancer Centre
Assays for circulating tumour cells utilize cell capture with antibodies to membrane antigens and characterization by either a) immunohistochemistry and cell counting or b) gene expression analysis. These assays provide prognostic information for patients with breast, colon and prostate cancer, and for predictive use in the early assessment of response to chemotherapy. |
|
09:30 |
Methylation Markers for Early Detection of Prostate Cancer and Risk Prediction
Mohammad Hoque, Assistant Professor, Johns Hopkins University
Further development of the non-invasive QMSP assay in urine and serum DNA will facilitate for early detection, surveillance and risk assessment of prostate cancer. |
|
10:00 |
Coffee Break and Networking in the Exhibition Hall |
|
10:45 |
Refining or Redefining Pathological Cancer Diagnosis with Microarray based Gene Expression Profiling: Myth or Reality? And Taking Account of the Obstacles
Zoltan Szallasi, Professor, Danish Technical University
The success of identifying reliable biomarkers is highly dependent on our ability to extract robust, consistent information from high throughput clinical data. The presentation will show two methods that increase the reliability and robustness of clinical microarray measurements with a special emphasis on breast cancer. |
|
11:15 |
Metastatic Skin Melanoma Biomarkers
Monica Neagu, Head of Immunobiology Laboratory, Victor Babes National Institute
Skin melanoma has an aggressive metastasis potential and detecting biomarkers is a prerequisite for evaluating the clinical outcome and therapy efficiency. The group followed patients in stages I-IV, for 18 months registering the dynamics of seric and peripheral immune cell markers. |
|
11:45 |
Genotype and Haplotype Analysis of TP53 Gene and Risk of Sporadic Colorectal Cancer
Veronika Polakova, PhD Student, Institute of Experimental Medicine - Academy of Sciences of the Czech Republic
The results, suggesting that prevalent haplotypes within the TP53 gene account for population based differences in CRC risk, will be presented. Significantly increased risk of both colon and rectal cancers in association with A1GCG and A2CCG haplotypes will be documented. |
|
12:15 |
Lunch and Networking in the Exhibition Hall |
|
13:15 |
Poster Viewing |
|
Disease Biomarkers
Chaired by Patrick Müller, Novartis Pharmaceuticals |
|
14:00 |
Tissue-Specific, Non-Invasive Biomarkers in (Pre-)Clinical Safety Assessment
Patrick Müller, Project Leader - Safety Assessment, Novartis Pharmaceuticals
A variety of novel, non-invasive, highly-specific biomarkers for target organ toxicities are considered for safety evaluation early during (pre-)clinical drug development. |
|
14:30 |
Discovery of Protein Biomarkers for Schizophrenia in Serum using Label-Free Relative Quantitation by nanoLC-MSE
Yishai Levin, PhD Student, University of Cambridge
In one of the group’s current studies, serum samples taken from first-onset, drug-naïve schizophrenia patients and healthy controls were investigated using nanoUPLC-MSE technology. This will be presented along with the significantly altered proteins found and validated in this large-scale study. |
|
15:00 |
Analysis of Lipase Level in Cord Blood, as a Marker for Acute Pancreatitis, Leading to Cystic Fibrosis
Ramasubramaniyan Kumarasamy, Student, SRM University
The presentation will describe the possibilities of a novel method to find the suitable biomarker in umbilical cord blood for identifying high risk newborn babies with cystic fibrosis. |
|
15:30 |
Coffee Break and Networking in the Exhibition Hall |
|
16:15 |
Pyrolisis – GCMS for Characterization of Polimixin and Colistimethate
Rui Oliveira Macêdo, Researcher, Federal University of Paraiba
Polimixin and colistimethate are active drug substances used for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Both drugs present isophorms with different pharmacological activities. Pyrolisis-GCMS is proposed to characterize changes in composition of isophorms of these antibiotics. |
|
16:45 |
Glycans in the Progression of HCV Infection to Hepatocellular Carcinoma
Radoslav Goldman, Assistant Professor, Georgetown University
Mass spectrometric analysis of N-glycans allows tracking of the natural progression of HCV infection to liver disease. The group identified N-glycans that predict HCC with 90% accuracy. The results provide leads for further improvement of analytical strategies in biomarker discovery. |
|
17:15 |
Drinks Reception in the Exhibition Hall |
Day Two - 17 October
|
Disease Biomarkers (continued)
Chaired by Mathias Uhlén, Royal Institute of Technology, Stockholm |
|
09:00 |
Stephen Barnhill, Chairman and Chief Executive Officer, Health Discovery Corporation |
|
09:30 |
Presentation to be confirmed |
|
10:00 |
Coffee Break and Networking in the Exhibition Hall |
|
Discovery Resources
Chaired by Mathias Uhlén, Royal Institute of Technology, Stockholm |
|
10:45 |
A Human Protein Atlas for Biomarker Discovery
Mathias Uhlén, Professor, Department of Biotechnology, AlbaNova University Centre, Royal Institute of Technology, Stockholm
A Human Protein Atlas (www.proteinatlas.org) for protein expression and localization profiles in human tissues, cancers and cell lines has been created. This publicly available portal can be used for in silico biomarker discovery and as a starting point for validation studies in various patient cohorts. |
|
11:15 |
Molecular Tools to Search for Biomarkers
Masood Kamali-Moghaddam, Researcher, Uppsala University
This presentation will illustrate a set of molecular tools with very high sensitivity and specificity for detection and localization of proteins and their interactions. Furthermore, the application of the methods in the search for biomarkers will be discussed. |
|
11:45 |
Presentation to be confirmed |
|
12:15 |
Lunch and Networking in the Exhibition Hall |
|
13:15 |
Poster Viewing |
|
Discovery Methods
Chaired by Tomasz Baczek, Medical University of Gdansk |
|
14:00 |
Companion Diagnostic Breath Tests for Oncology Drugs
Anil Modak, Associate Director, Cambridge Isotope Laboratories
In vivo breath tests for personalized medication of oncology drugs metabolized by polymorphic enzymes. |
|
14:30 |
Evaluation of Normalization Algorithms using an Extensive List of Matched Quantitative RT-PCR and Clinical Microarray based Gene Expression Measurements
Balázs Györffy, Senior Scientific Fellow, Joint Research Laboratory of the Hungarian Academy of Sciences and the Semmelweis University
Is a consistent measurement of gene expression level by microarrays and QRT-PCR possible? The presentation will show a benchmark dataset to quantify close to a hundred genes on clinical cancer samples and show the distinction between the performance of various available normalization algorithms. |
|
15:00 |
Poster Award |
|
15:10 |
Coffee Break and Networking in the Exhibition Hall |
|
15:50 |
Quantitative Profiling of Bile Acids in Biofluids and Tissues: Compound Class Targeting in a Metabolomics Workflow
Ivana Bobeldijk-Pastorova, Senior Project Manager and Scientist, TNO Quality of Life
A new method combining comprehensive endogenous metabolite profiling and quantitative determination of bile acids will be presented, including applications. |
|
16:20 |
Predictions of Peptides’ Retention Times in Liquid Chromatography as a Supportive Tool to Improve Protein Identification in Proteomics
Tomasz Baczek, Associate Professor, Medical University of Gdansk
One of initial steps of proteomic analysis is peptides separation. However, little bioinformatics benefits from liquid chromatography separation data are still drawn. Prediction of retention times for peptides, combined with mass spectrometry data, could improve the confidence of protein identifications. |
|
16:50 |
Close of Conference | |